Day: May 17, 2022

Predictive maintenance is essential for the oil and gas industry LONDON, May 17, 2022 (GLOBE NEWSWIRE) — Older oil and gas facilities have been more at risk of unplanned downtime. These also may contribute to excess greenhouse emissions. Using predictive maintenance techniques, the performance of older equipment can be improved. The COVID-19 pandemic has also sensitized the oil and gas industry to the perils of shortages of skilled maintenance crew, especially in the case of equipment breakdowns in remote locations. Predictive maintenance can also help improve human resource allocation, thereby increasing productivity. The Predictive Maintenance in the Oil and Gas Industry – Thematic Research Report offered by GlobalData Plc provides an overview of the predictive maintenance strategies in the oil & gas industry. It highlights...

The management board of the Estonian Financial Supervision and Resolution Authority decided to approve AS LHV Group as a parent company operating as a financial holding company. LHV Group is a holding company whose subsidiaries include a credit institution, an asset management company and a non-life insurance company. In addition, LHV Group is establishing a new bank in the United Kingdom. The need to apply for approval arose from the amendment to the Credit Institutions Act and the granting of the approval does not entail any changes in the activities or management of LHV Group nor its subsidiaries. The Estonian FSA has also previously exercised supervision over LHV Group on a consolidated basis.Priit RumCommunication ManagerPhone: +372 502 786Email: priit.rum@lhv.ee 

Roseville, MN, May 17, 2022 (GLOBE NEWSWIRE) — Hawkins, Inc. (Nasdaq: HWKN), a leading specialty chemical and ingredients company, announced today it will participate in the 3rd Annual Loop Capital Markets Investor Conference. The conference will take place June 1-2, 2022. The first day (June 1) will be virtual 1×1 and group meetings. The second day (June 2) will be in-person 1×1 and group meetings at the Westin New York Times Square (270 West 43rd Street). Hawkins management will participate virtually on June 1. To schedule a one-on-one meeting with management, please contact your Loop Capital Markets representative, or Hawkins Investor Relations at ir@hawkinsinc.com. About Hawkins, Inc. Hawkins, Inc. was founded in 1938 and is a leading specialty chemical and ingredients company that formulates, distributes, blends...

Atlanta, May 17, 2022 (GLOBE NEWSWIRE) — UC Asset LP (OTCQX: UCASU) announces that it will start to deliver $0.10/share dividend for its shareholders who held UCASU common shares by December 31, 2021. “Our shareholders can expect receiving checks in the coming weeks, since our 2021 financial statements have completed being audited, and we have filed our annual report on Form 1-K by the end of last week,” declares Greg Bankston, managing partner of UC Asset. For the year of 2021, UC Asset reports a $0.12 per share net income. This net income, combined with a $0.03 per shear net equity increase resulting from buyback of shares, will likely lead to a $0.15 per share net equity increase. The $0.12 per share net income represents a 330% net profit growth over the previous year.  The company also reports a 73% operating profit growth...

Socazolimab (anti-PD-L1 monoclonal antibody) was discovered by Sorrento from its fully human antibody G-MABTM library and licensed by China Oncology Focus Limited (“COF”), a Lee’s Pharm subsidiary, for the Great China Territories. COF has completed the patient enrollment (498 patients) for a Phase III, multicenter, randomized, double blinded, placebo-controlled clinical trial of Socazolimab combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer (“ES-SCLC”).SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that its license partner, China Oncology Focus Limited (“COF”), a subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm”), has completed the patient enrollment for a Phase III, multicenter, randomized,...

Los Angeles, California, May 17, 2022 (GLOBE NEWSWIRE) — Crown Electrokinetics Corp. (NASDAQ: CRKN) (“Crown” or the “Company”), a leading smart glass technology company, reported today its financial results for the first quarter 2022 in an earnings call held on May 13, 2022. Mr. Doug Croxall, Crown’s CEO and Mr. Joel Krutz, CFO, shared with the Company shareholders and industry analysts, the results of the first quarter ending March 31, 2022. In addition to earnings updates, the call also included updates to financing, vertically integrated production, organizational restructuring, and first-generation product delivery. Call highlights:Mr. Croxall delivered a detailed description of the product feature set and capabilities for the first generation and expected second generation Smart Window Inserts™. In...

stā BODY’s First Livestream Shopping Event is Scheduled for May 19, 2022 at 2 p.m. PT The global shapewear market is anticipated to reach USD $3.7 billion by 2028, and stā BODY leverages MARKET’s shoppable livestream capabilities to reach this booming audience. NEWPORT BEACH, Calif. and SALT LAKE CITY, May 17, 2022 (GLOBE NEWSWIRE) — Verb Technology Company, Inc. (Nasdaq: VERB) (“VERB” or the “Company”), the leader in interactive video-based sales-enablement applications, including shoppable livestream video, today announced a new partnership with boutique women’s shapewear brand stā BODY. The brand will begin hosting livestream shopping events on MARKET, VERB’s livestream shopping platform, on May 19, 2022 at 2 p.m. PT. The events will be livestreamed from stā BODY’s standalone store on MARKET at stabody.market.live. Created...

STOCKHOLM, SWEDEN, May 17 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has completed the acquisition of the privately-held US-based biotechnology company Atrin Pharmaceuticals Inc. Aprea Therapeutics will now prioritize the development of Atrin Pharmaceuticals’ drug candidates, which are being developed to fight cancer by affecting the proteins involved in the ability of tumors to repair damage to their DNA. With the acquisition of Atrin Pharmaceuticals’ portfolio of candidate drugs, Aprea Therapeutics intends to shift its primary focus to the development of ATRN-119, a drug candidate that inhibits an important signaling pathway in DNA damage repair. ATRN-119 will soon be evaluated in clinical phase 1/2a studies in the treatment of malignant solid tumors, both as monotherapy...

–Prospective location close to coastal shipping and infrastructure to proceed with explorationFigure 1 – Alpha Copper, Okeover (‘Ok”) Property